Genentech, a member of the Roche Group (SIX: RO, ROP; OTCQX: RHHBY), announced today new data from the positive Phase III FENhance 1 and 2 studies, which met their primary endpoint. The studies showed ...
Micromanaging, unhelpful colleagues and the threat of job loss – workers tell CNA about the costs of flexibility in the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results